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ABSTRACT
Objective: Cancer and its treatment have an influence on health-related quality of life (HRQOL).
Normative data could help to interpret HRQOL among cancer patients. Our aim was to generate longi-
tudinal normative data based on sex, age and morbidity for the European Organisation for Research
and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Methods: The QLQ-C30 and the Self-administered Comorbidity Questionnaire were administered to a
representative panel of the Dutch-speaking population in the Netherlands in 2009 (n¼ 1743), 2010
(n¼ 2050), 2011 (n¼ 2040), 2012 (n¼ 2194) and 2013 (n¼ 2333).
Results: Regarding sex, at baseline, women scored statistically significant and clinically relevant worse
on fatigue, pain and insomnia compared to men. Regarding age groups and sex, HRQoL was lower
among the older age groups in men and women. For men, at baseline, significant and clinically rele-
vant age differences were found on physical, role and cognitive functioning, global QOL scale, fatigue,
pain and dyspnea. The change over 5 years was larger for older age groups. For women, at baseline,
significant and clinically relevant age differences were found on physical functioning, role functioning,
nausea/vomiting, pain, dyspnea and insomnia. Those without self-reported morbidities reported a bet-
ter HRQoL compared to those with morbidities. Among those who completed five assessments, the
summary scale scores were stable over time, were higher in men than in women, and higher in
younger compared to older age groups.
Conclusions: Although HRQoL remains relatively stable over time, HRQoL data needs to be interpreted
with care as many confounding factors can have an impact on HRQOL. Our data (which is freely avail-
able) can aid in the interpretation of QLQ-C30 scores and can help increase our understanding of the
influence of age, sex, time and morbid conditions on HRQoL among cancer patients.
Abbreviations: EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire C30; SCQ: Self-administered Comorbidity Questionnaire
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Introduction
The assessment of health-related quality of life (HRQOL)
among cancer patients has gained importance over the past
decades and is now considered to be standard in most clinical
studies. One of the most widely used questionnaires to assess
HRQOL is the European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire C30 (EORTC
QLQ-C30) [1]. This questionnaire was developed by the EORTC
to assess HRQOL of cancer patients and it can be supple-
mented by disease-specific modules. The QLQ-C30 has good
psychometric properties and is responsive to change [1,2]. A
quick search of the literature on PubMed shows that at least
2500 publications report on this questionnaire and it has been
translated and validated in over a 100 languages [3].
Although the QLQ-C30 is being used repeatedly to assess
HRQOL, and the clinically relevant differences in QLQ-C30
scores between and within subjects have been established
[4,5], its interpretation is at times challenging due to the lack
of cutoff points for ‘low’, ‘acceptable’ or ‘good’ HRQOL [6].
Yet, it is almost impossible to make these distinctions since
HRQOL differs tremendously across individuals and situations.
This makes the interpretation of HRQOL more difficult com-
pared to, for instance, the interpretation of depression scores
in which cutoffs have been established [7]. Also, a true base-
line assessment of HRQOL before diagnosis and treatment of
cancer is almost always lacking. The availability of QLQ-C30
reference data from general population samples improved its
interpretability tremendously. Reference data is now available
for an increasing number of, mostly European, countries
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[8–10]. With reference data, one can compare HRQOL scores
of a certain cancer patient sample to age- and sex-matched
normative data from the general population without cancer
in order to see the true effect of cancer and its treatment.
Together with the established clinically important differences
by Cocks et al. [4] (e.g., the smallest difference that patients
notice and perceive as moderately beneficial), this allows
researchers to estimate whether HRQOL differs between can-
cer patients and the general population in a clinically mean-
ingful way. In order to make proper comparisons with cancer
patient populations’ possible, reference data is preferably
presented according to age, sex and morbid conditions, since
they have a profound impact on HRQOL [6,11].
Although some studies compared reference data between
populations of different countries [9,10,12,13], or between
different samples over time in a single country [10,11], longi-
tudinal normative data on the QLQ-C30 has not been
reported previously in the literature. The availability of longi-
tudinal QLQ-C30 normative data could enhance the interpret-
ation of longitudinal studies among cancer patients since it
helps interpreting whether changes in HRQOL are due to
cancer or to ageing and the presence of morbidity.
Therefore, our primary aim was to present Dutch normative
data for the QLQ-C30 collected in five consecutive years. We
also present normative data for different subsamples by strat-
ifying the total sample by sex, age and morbid conditions.
Material and methods
Setting and study population
Normative data were derived from the Health and Health
Complaints project from CentERdata (www.centerdata.nl). In
short, CentERdata has an online household panel (i.e., the
CentERpanel) which consists of about 2000 households. This
panel is representative of the Dutch-speaking population in
the Netherlands, including those without Internet access. The
latter are provided with broadband access and a personal
computer. Members of the CentERpanel of 18 years and
older completed the QLQ-C30. This sample has been
described previously [14].
The initial CentERpanel sample was drawn in cooperation
with Statistics Netherlands (CBS), by Random Digit Dialling. In
order to be able to compensate for potential attrition during
the four-year assessment, a reserve pool of panel members
were gathered by selecting a random sample of addresses
from a mailing addresses database. Then, a random sample
of potential new members was interviewed by telephone or
by mail. If the person was willing to participate in survey
research, the household was included in a database of poten-
tial panel members. In case a participating household drops
out of the panel, a new household is selected from this
database based on demographic characteristics in order to
maintain a representative panel of the adult, Dutch-speaking
population.
Panel members received online questionnaires in
November 2009, 2010, 2011, 2012 and 2013. Nonrespondents
were reminded a week later.
Study measures
Sociodemographic data that were collected include age,
gender, living situation (with partner and/or children), educa-
tion, income, work situation and degree of urbanization of
residence.
HRQOL was assessed with the Dutch version of the EORTC
QLQ-C30 (Version 3.0) [1]. It contains five functional scales on
physical, role, cognitive, emotional and social functioning, a
global QOL scale, three symptom scales on fatigue, nausea/
vomiting, pain and six single items assessing dyspnea, insom-
nia, loss of appetite, constipation, diarrhea and financial
impact. Each item is scored on a four-point Likert-scale,
except the global QOL scale, which has a seven-point Likert-
scale. Scores were linearly transformed to a 0–100 scale [15].
Besides the global QOL scale, a single higher-order summary
score was calculated, using 27 out of the 30 items (excluding
global quality of life and financial impact) [16,17]. A higher
score on the functional scales, the global QOL scale and sum-
mary score means better functioning and HRQOL, whereas a
higher score on the symptom scales means more complaints.
Though this questionnaire was developed for cancer patients,
the questions are appropriate for any respondent, as they are
quite general. Examples of questions are; ‘Do you have any
trouble taking a long walk?’ (physical functioning scale),
‘Have you vomited?’ (nausea/vomiting symptom scale) and
‘Have you had trouble sleeping?’ (insomnia single item).
Self-reported morbid conditions were assessed with an
adapted Self-administered Comorbidity Questionnaire (SCQ)
[18]. Patients were asked whether they currently had asthma/
COPD, depression, diabetes mellitus, heart disease, hyperten-
sion, osteoarthritis, rheumatoid arthritis, stroke, stomach-, kid-
ney- or liver-disease and thyroid condition or whether they
had had any of these conditions in the past 12 months.
Information on whether they had cancer in the past was
obtained via a separate question.
Statistical analyses
Routinely collected data from the CentERpanel on panel
characteristics enabled us to compare the group of nonres-
pondents with respondents, using analysis of variance
(ANOVAs) for continuous variables and chi-square tests for
categorical variables. The same tests were used to analyze
sociodemographic differences between participants who
completed only one questionnaire and those who completed
two or more questionnaires and to compare participant char-
acteristics according to sex.
For purposes of comparison with other studies, mean
scores are reported in 10-year age groups for men and
women separately, with the exception of the youngest
(18–29 year) and oldest age groups (70–92 year) due to small
numbers. ANOVAs were conducted to assess differences in
EORTC QLQ-C30 scores by sex, by age groups and sex and
by self-reported morbidities in (1) mean EORTC baseline sub-
scale scores; (2) mean change scores per year (first the
change scores between two consecutive time points were
calculated and second the mean of the total of change
scores was calculated, only for patients who completed at
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least two questionnaires) and (3) change scores over 5 years
(defined as the change between T1 and T5).
For patients who completed all five questionnaires, we
graphically present mean scores over time for three scales:
physical functioning, global quality of life and the EORTC
summary score. The global quality of life scale is the most
commonly reported scale, the physical functioning scale is
recommended by the Food and Drug Administration (FDA)
as the sole functional outcome [19], while the overall sum-
mary score encompasses both functioning and symptoms
and might therefore be most reliable [16,20].
Analyses were performed in IBM SPSS 24.0 (IBM SPSS
Statistics, Armonk, NY, USA) and we used a significance level
of a¼ .05. Clinically meaningful differences between QLQ-C30
baseline scores were determined using the guidelines for
interpretation of the QLQ-C30 ‘between groups’ [4]. Since a
guideline for the interpretation of the emotional functioning
scale and summary score was lacking from these guidelines
[4], we used the guideline for the role functioning scale
instead because this one is the strictest. ‘Within a group’,
clinical relevant differences over time were defined as a 10
point or more difference [5].
Participants characteristics are provided for all participants
in Table 1, only those that completed at least two question-
naires were included in further analyses, only those that com-
pleted the first and the last questionnaire were included in
the 5-year change scores. The results will be discussed per
subgroup.
Results
Sample characteristics
Questionnaires were filled out by participants from the
CentERpanel in 2009 (n¼ 1743), 2010 (n¼ 2050), 2011
(n¼ 2040), 2012 (n¼ 2194) and 2013 (n¼ 2333). Of the 3483
individuals that completed a questionnaire during the 5 years
of the study, 1197 individuals responded to both the 2009
Table 1. Sociodemographic characteristics of the sample from the Health and Health Complaints project of CentERdata at T1.
N (%)
Men (n¼ 1346) Women (n¼ 1193) Total (n¼ 2539)
p Value
(comparing men and women)
Mean age (years) 54.2 (15.5) 50.1 (15.3) 52.3 (15.5) <.0001
Age category (years) <.0001
18–29 90 (6.7) 97 (8.1) 187 (7.4)
30–39 181 (13.4) 257 (21.5) 438 (17.3)
40–49 219 (16.3) 209 (17.5) 428 (16.9)
50–59 295 (21.9) 256 (21.5) 551 (21.7)
60–69 337 (25.0) 244 (20.5) 581 (22.9)
70–92 224 (16.6) 130 (10.9) 354 (13.9)
Living situation <.0001
Single 220 (16.3) 254 (21.3) 474 (18.7)
Living with partner, without children 654 (48.6) 451 (37.8) 1105 (43.5)
Living with partner and children 429 (31.9) 409 (34.3) 838 (33.0)
Single with children 19 (1.4) 58 (4.9) 77 (3.0)
Other 24 (1.8) 21 (1.8) 45 (1.8)
Education <.0001
Elementary school 56 (4.2) 63 (5.3) 119 (4.7)
High school 485 (36.1) 498 (41.8) 983 (38.8)
Vocational school 590 (43.9) 505 (42.4) 1095 (43.2)
University 212 (15.8) 124 (10.4) 336 (13.3)
Employment <.0001
Paid job/self-employed 763 (56.7) 597 (50.0) 1360 (53.5)
Retired 436 (32.4) 177 (14.8) 613 (24.1)
Work disabled 44 (3.3) 64 (5.4) 108 (4.3)
Unemployed 24 (1.7) 22 (1.9) 46 (1.8)
Student 46 (3.4) 41 (3.4) 87 (3.4)
Other 33 (2.4) 292 (24.4) 325 (12.9)
Family-income (net per month) <.0001
e1150 or less 57 (4.2) 103 (8.6) 160 (6.3)
e1151–e1800 212 (15.8) 235 (19.7) 447 (17.6)
e1801–e2600 372 (27.6) 327 (27.4) 699 (27.5)
>e2600 704 (52.3) 526 (44.1) 1230 (48.4)
Urbanization home (addresses/km2) .633
Very strong (2500) 194 (14.5) 176 (14.9) 370 (14.7)
Strong (1500–2500) 361 (26.9) 295 (24.9) 656 (26.0)
Moderate (1000–1500) 267 (19.9) 250 (21.1) 517 (20.5)
Little (500–1000) 278 (20.7) 264 (22.3) 542 (21.5)
Not (<500) 240 (17.9) 200 (16.9) 440 (17.4)
Self-reported morbidities (in past 12 months)
No health problems 215 (40.0) 177 (41.2) 392 (40.5) .742
Heart disease 160 (11.9) 54 (4.5) 214 (8.5) <.0001
Hypertension 305 (22.7) 227 (19.1) 532 (21.0) .026
Asthma/COPD 106 (7.9) 131 (11.0) 237 (9.4) .007
Cancer 96 (7.1) 90 (7.5) 186 (7.3) .691
Diabetes mellitus 92 (6.9) 63 (5.3) 155 (6.1) .103
Bold values represent significant differences between men and women.
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and 2013 questionnaire (34.4%), 967 individuals filled out all
questionnaires (27.8%) and 2539 filled out at least two ques-
tionnaires in time (72.9%).
Sociodemographic and clinical characteristics of
respondents at T1
The group of respondents at baseline (i.e., the first question-
naire of a participant, whether it was 2009, 2010, 2011, 2012
or 2013) consisted of 1364 men and 1193 women with a
mean age of 52.3 (Table 1). The women were significantly
younger (p< .001), more often single (with or without chil-
dren; p< .0001) and lower educated (p< .0001). Men were
more often working or retired (p< .001) and reported a
higher family income (p< .001). No differences between men
and women were found regarding urbanization.
Regarding self-reported morbidities as assessed with the
adapted SCQ, 40.5% (n¼ 392) of the respondents reported
no morbid conditions in the past 12 months. A self-reported
cancer diagnosis was present in 7% of the participants. Men
more often reported having been diagnosed with heart dis-
ease (12 vs. 4.2%; p< .001) in the past 12 months compared
to women, and they less often reported a diagnosis of
anemia (1.1 vs. 3.7%; p¼ .008), thyroid disease (1.1 vs. 4.9%;
p< .001), depression (3.2 vs. 7.2%; p¼ .04), rheumatoid arth-
ritis (3.5 vs. 7.7%; p< .001) and osteoarthritis (14 vs. 24%;
p< .0001).
Differences between respondents who completed one or
at least two questionnaires
In comparison with those who filled out one questionnaire,
those who filled out at least two were older (52.3 years vs.
42.1 years; p< .0001), more often male (53% male vs. 48%
male; p< .001), retired (24.1% retired vs. 12.3% retired;
p< .0001), had a lower monthly net income (e1644.7 vs.
e1766.1; p< .001), lower educated (high school or lower 43.5
vs. 33.1%; p< .0001), more often single (22.1% single vs.
17.6% single; p< .0001) and had fewer people in their house-
hold (2.5 vs. 2.8; p< .0001). Also, they reported more morbid
conditions (1.1 vs. 0.6; p< .0001). Specifically, they were more
often diagnosed with cancer (7.3% vs.5.25; p< .05), a heart
condition (8.5% vs. 4.4%; p< .0001), high blood pressure
(21% vs. 11.1%; p< .0001), diabetes (6.1% vs. 2.6%;
p< .0001), osteoarthritis (15.1 vs. 9.0 p< .0001) and rheuma-
toid arthrosis (4.9% vs. 2.0%; p< .0001). With respect to the
QLQ-C30, those who filled out at least two questionnaires
reported lower scores on fatigue (mean 17.4 vs. 20.8;
p< .0001) and appetite loss (3.2 vs. 4.5; p< .01), and higher
scores on emotional functioning (88.8 vs. 84.8; p< .0001)
compared to people who completed one questionnaire.
However, these differences were not clinically relevant.
EORTC QLQ-C30 by sex
From this point forward, only those that completed at least
two questionnaires were included in our analyses. At base-
line, women scored statistically significantly worse on all
functioning scales, the global QOL scale and summary scale,
all symptoms scales and all single items compared to men
except for diarrhea (all p’s< .0001; Table 2). This was only
clinically relevant for fatigue, pain and insomnia.
Furthermore, women showed a significantly lower mean
change per year on physical functioning (p< .0001), the sum-
mary score (p< .05) and fatigue (p< .001) but this was not
clinically relevant. Finally, no significant differences were
found between men and women regarding their change
over 5 years.
EORTC QLQ-C30 by age groups and sex
Scores slightly fluctuated but in general HRQoL was lower
among the older age groups. For men, at baseline, significant
age differences were found on physical, role, emotional, cog-
nitive and social functioning, the global QOL scale, the sum-
mary score, fatigue, pain, dyspnea and constipation (Table 2).
The differences in physical, role and cognitive functioning,
global QOL scale, fatigue, pain and dyspnea were clinically
relevant. For men, mean change per year was higher among
older age groups for physical functioning (p¼ .041) but this
was not clinically relevant. The change over 5 years was
larger for older age groups for physical functioning
(p< .0001), the summary score (p¼ .035) and insomnia
(p¼ .045) among men but this was not clinically relevant.
For women, at baseline, significant age differences were
found on physical functioning, role functioning, the summary
score, nausea/vomiting, pain, dyspnea and insomnia (Table
2). These differences were all clinically relevant except for the
summary score. Moreover, mean change per year for women
was higher among older age groups for physical functioning
(p¼ .03) and fatigue (p¼ .041) but this was not clinically rele-
vant. Lastly, no changes between age categories were found
in 5 years change scores among women.
EORTC QLQ-C30 by age groups and sex over time
Among those who completed five assessments, the scores on
the physical functioning scale and the summary scale were
quite stable over time within the different age categories
(Figure 1). However, there was a clear decrease in the oldest
age group (70þ) over the five-year period. The scores on the
global QOL scale were less stable and fluctuated more over
time within most age categories between both men and
women. Furthermore, the scores on the global QOL scale, the
physical functioning scale and the summary scale were
higher in men than in women and higher in the younger
age groups compared to the older age groups.
EORTC QLQ-C30 by self-reported morbid conditions
At baseline, respondents with asthma/COPD, joint disease
and depression reported a significantly worse HRQoL on
almost all scales and single items compared to those without
any morbid conditions (except on appetite loss among those
with joint disease and diarrhea among those with joint dis-
ease and depression) (Table 3). Those with heart disease,
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hypertension or diabetes now or in the past 12 months
reported a lower HRQOL on some of the QLQ-C30 subscales
and items. Those ever diagnosed with cancer also reported a
lower HRQOL on some QLQ-C3- subscales and items. These
differences were all clinically relevant except constipation
among asthma/COPD patients and appetite loss among can-
cer patients. No clinically relevant differences were found
regarding mean change per year and the change over 5
years.
Discussion
Results of this 5-year longitudinal study among the general
Dutch population showed that at baseline, women scored
statistically significant and clinically relevant worse on
fatigue, pain and insomnia compared to men. Regarding age
groups and sex, HRQoL was lower among the older age
groups in men and women. For men, at baseline, significant
and clinically relevant age differences were found on phys-
ical, role and cognitive functioning, global QOL scale, fatigue,
pain and dyspnea. For women, at baseline, significant and
clinically relevant age differences were found on physical
functioning, role functioning, nausea/vomiting, pain, dyspnea
and insomnia. Those without self-reported morbidities
reported a better HRQoL compared to those with morbid-
ities. Among those who completed five assessments, the
summary scale scores were stable over time, were higher in
men than in women, and higher in younger compared to
older age groups.
Women reported a worse HRQoL compared to men, which
is in line with other studies [9,13,21–23]. However, women
reported a significantly lower mean difference per year on
physical functioning, the summary score and fatigue com-
pared to men. Probably, because they reported a worse
Figure 1. EORTC QLQ-C30 scores by sex and age over time. Figure is based on data from those that completed five assessments (n¼ 967).
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HRQOL than men from the start. Nevertheless, no significant
differences were found between men and women regarding
their change in 5 years.
In general, HRQOL was lower among the older age groups
in both men and women which was also found in previous
studies [9,13,21–23]. Furthermore, change scores were higher
in physical functioning per year in the older age groups indi-
cating faster decrease. Similar data has not been reported
previously on this topic. Our results might, at least partially,
be explained by the general increase in morbid conditions
that is associated with age.
As we reported previously [12], the EORTC QQL-C30 is per-
fectly able to discriminate between those with and without
self-reported morbid health conditions. In general, those with
chronic health conditions reported a significantly lower
HRQoL, than those without such conditions. This finding con-
firms the results of a Norwegian and Swedish study [23,24].
Also, a study among the general Korean population showed
that an increase in the number of somatic diseases was asso-
ciated with lower QLQ-C30 scores [9]. Overall, QLQ-30 refer-
ence data among those with various morbid conditions is
valuable for use in studies including cancer patients, since
they often have morbid conditions. Especially long after the
diagnosis of cancer, the morbid condition or its treatment
can be more strongly related to a patients’ HRQOL than can-
cer itself.
This study had a number of limitations. For instance, our
normative data did not include many elderly while the preva-
lence of cancer increases with age. In a new study, we will
solve this by oversampling elderly persons. Also, our data
was collected in the Netherlands, which is a relatively rich
and prosperous country with excellent access to affordable
and high quality health care. Results are therefore only repre-
sentative for western countries at best while comparison
with other countries is difficult. In addition, we found differ-
ences in age, sex, work, education, income, marital status,
household and morbid conditions between those who filled
out one questionnaire versus those who filled out at least
two, so this indicates possible response bias or selection bias.
Furthermore, not all patients completed all assessments
which could be a sign of selection bias. It is possible that
only the healthiest participants had the energy to keep com-
pleting questionnaires every year. The other way around is
also possible, perhaps only those with health complaints felt
the need to report this year after year. Furthermore, our data
on morbid conditions were self-reported which is less reliable
compared to clinical examinations. One of the strengths of
this study is the fact that this is the first study that presents
longitudinal normative data collected over a period of 5
years. This provides insight into the natural course of HRQOL
in the general population and is helpful in the interpretation
of longitudinal QLQ-C30 data of cancer patients. In addition,
the CentERpanel is not biased by socioeconomic status of
computer literacy because all panel members were initially
contacted by mail and phone, and those without internet/
computer capabilities were provided with them. Another
strength is the use of an online questionnaire which usually
results in more complete data compared to paper and pencil
questionnaires [25] and does not decrease overall response
rates [26]. Finally, the raw normative data presented in this
study is freely available for noncommercial research purposes
via the PROFILES registry (see www.profilesregistry.nl for
conditions of use). This enables researchers to select age--
matched normative data suitable for their own research
purpose.
In conclusion, our results demonstrate that HRQOL data
needs to be interpreted with care as many confounding fac-
tors might have an impact on HRQOL. For instance, this art-
icle showed that there is an urgent need to include age,
gender and morbidity into account when reporting on
HRQOL outcomes. Of course, other background characteris-
tics can be considered as well. In general, longitudinal popu-
lation-based reference values are an important tool in the
interpretation of HRQOL among cancer patients. They can be
used to compare QoL-courses of cancer patients with norma-
tive data to investigate potential response shift in the cancer
group. Also, they can be used to control for effects that arose
by repeated assessment with the same instrument (e.g.,
habituation). The fact that QLQ-C30 scores were worse
among those with morbid conditions may improve the
understanding of the influence of comorbid health condi-
tions on HRQOL among cancer patients. Our longitudinal ref-
erence data will hopefully facilitate better interpretation of
QLQ-C30 results among cancer patients by providing age-
and gender-specific norms and change scores from the gen-
eral population. Besides its usefulness for research papers,
our data can be used to offer feedback to patients on their
HRQOL by giving a graphical overview of patients’ own
scores (over time) in comparison with those of a normative
population of the same age and sex (over time) [27]. As this
is the first publication on longitudinal reference data of the
QLQ-C30, replication is recommended, especially in other
countries.
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